clonoSEQ
NGS MRD Monitoring

View clonoSEQ Overview

What is MRD?

Even if you are responding well to treatment or are in remission, a small number of cancer cells can remain in your body, and may cause your disease to return. This is called measurable (or minimal) residual disease, also known as MRD.

learn more about MRD

clonoSEQ leverages the power of next-generation DNA sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission.

How clonoSEQ works

News and Updates

At Adaptive, we are leveraging the immune system’s natural ability to detect and treat disease to develop clinical products. Understanding the immune response to COVID-19 may lead to solutions to accelerate progress against the disease.

View Landing Page

May, 2020
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing.

View Press Release

April, 2020
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19.

View Press Release

This page is intended for use by healthcare professionals outside of the United States.

The clonoSEQ Assay B-Cell Reagent Set is CE marked as an in vitro diagnostic (IVD) for assessing the MRD status and changes in disease burden during and after treatment in B-cell malignancies in DNA extracted from blood and/or bone marrow samples.

The clonoSEQ Assay is being utilized for a variety of investigator-sponsored clinical trials in B-cell lymphoid cancers. If you are interested in learning more about use of clonoSEQ in your own trials, contact dxsupport@adaptivebiotech.com.

Contact Us

Make an inquiry to learn more about our products.

Request Information